BioSpace News Archive

Bionomics Limited announced it will present data on BNC210 for the treatment of Social Anxiety Disorder at the 2023 American Society of Clinical Psychopharmacology Annual Meeting taking place Tuesday, May 30, 2023, through Friday, June 2, 2023, in Miami Beach, Florida.

PainTEQ announced that on May 24, 2023 , the Patent Trial and Appeal Board (PTAB) issued a final written decision in an inter partes review (IPR) proceeding directed to U.S. Patent No. 10,426,539 (539 Patent), handing PainTEQ a decisive victory.

Galvanize Therapeutics, Inc., a leader in developing pulsed electric field therapies for COPD, solid tumors and cardiac arrhythmias, announced today that the company has signed an exclusive license agreement with Energenx Medical, Ltd to develop and commercialize its products in Mainland China, Hong Kong, Taiwan, and Macau.

Numinus Wellness Inc. (TSX: NUMI) is pleased to announce that Cedar Clinical Research (CCR) has begun studying COMP360 psilocybin therapy, an investigational new therapy for treatment-resistant depression (TRD), as part of the largest-ever international clinical study of psilocybin therapy.

Castle Biosciences, Inc. recognizes the importance of Skin Cancer Awareness Month and is proud to continue its ongoing collaboration with The Sun Bus and The Skin Cancer Foundation in support of skin cancer prevention, research, education and advocacy.

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1 -Positive Non-Small Cell Lung Cancer.

Abstract published online in the Journal of Clinical Oncology supplement of the 2023 ASCO Annual Meeting Proceedings.

Alterity Therapeutics today announced it has commenced a new Phase 2 clinical trial of ATH434 in patients with Multiple System Atrophy (MSA) and the first patient has been enrolled.

OLON Group announces the start of construction of a new facility at its Rodano site which will be entirely dedicated to managing and producing Ultra-Potent compounds, used for example as payloads and payload-linkers for ADCs, one of the most promising emerging cancer therapies, which combines the effective killing power of small molecule cytotoxins and the highly specific targeting ability of monoclonal antibodies.

Kura Oncology, Inc. today announced that a late-breaking abstract with updated data from the Phase 1 trial of the Company’s menin inhibitor, ziftomenib, has been accepted for oral presentation at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany.